Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15099654 | 0.88 | KDM4E (0.35) | ALDH1A1SMN1; SMN2LMNAL3MBTL1RXFP1 | |
| SCHEMBL15093540 | 0.87 | PSIP1 (0.38) | ALDH1A1SMN1; SMN2LMNAL3MBTL1RXFP1 | |
| SCHEMBL15099740 | 0.86 | ALDH1A1 (0.36) | ALDH1A1MAPT | |
| SCHEMBL1699658 | 0.85 | ADORA3 (0.42) | ALDH1A1SMN1; SMN2L3MBTL1MAPTADORA3 | |
| SCHEMBL15093489 | 0.83 | ALDH1A1 (0.39) | TBK1ALDH1A1SMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL16657255 | 0.83 | ALDH1A1 (0.39) | TBK1ALDH1A1SMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL15099655 | 0.83 | SMN1; SMN2 (0.34) | TBK1ALDH1A1SMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL15093279 | 0.81 | SMN1; SMN2 (0.34) | ALDH1A1SMN1; SMN2LMNAL3MBTL1MAPT | |
| SCHEMBL15099650 | 0.81 | SMN1; SMN2 (0.34) | ALDH1A1SMN1; SMN2LMNAL3MBTL1MAPT | |
| SCHEMBL1699637 | 0.80 | ALDH1A1 (0.37) | ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9284323-B2 | Naphthalene acetic acid derivatives against HIV infection | GILEAD SCIENCES, INC. (US) | 2016-03-15 | — | — | US | disclosed |
| US-20150111891-A1 | NAPHTHALENE ACETIC ACID DERIVATIVES AGAINST HIV INFECTION | GILEAD SCIENCES, INC. (US) | 2015-04-23 | — | — | US | disclosed |
| US-20150111891-A1 | NAPHTHALENE ACETIC ACID DERIVATIVES AGAINST HIV INFECTION | GILEAD SCIENCES, INC. (US) | 2015-04-23 | — | — | US | disclosed |
| WO-2013103738-A1 | NAPTHALENE ACETIC ACID DERIVATIVES AGAINST HIV INFECTION | GILEAD SCIENCES, INC. (US) | 2013-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111891-A1 | NAPHTHALENE ACETIC ACID DERIVATIVES AGAINST HIV INFECTION | NFATC1, ACIN1, NAAA | TBK1 1541/4885ALDH1A1 114/4885SMN1; SMN2 2614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.